10[™] ANNUAL DIGESTIVE DISEASES: NEW ADVANCES

September 29–30, 2023 Hyatt Regency Jersey City On The Hudson

This activity is supported by educational grants from Cook Medical, CymaBay Therapeutics, Inc., Grifols, Mallinckrodt Pharmaceuticals, Olympus, and Salix Pharmaceuticals.

ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER Imparting knowledge. Improving patient care.

This activity is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Focus Medical Communications.

What's New Irritable Bowel Syndrome



Anthony Lembo, MD Director of Research Digestive Disease and Surgery Institute Cleveland Clinic Cleveland OH




- Consultant: Ironwood, Vibrant, Ardelyx, Gimotti, Pfizer, BioAmerica
- Advisory Board: Atmo, Takeda, Aeon, Allakos, Arena, Gemelli, Evoke
- Data Monitoring Safety Board: Iqvia

IBS is Chronic Disorder of Gut-Brain Interaction (DGBI)

- 30's-40's; ♀≥ ♂; 4-11% adult population
- Intermittent abdominal pain/discomfort/bloating and altered bowel function
- Symptoms are frequently aggravated by food/stress
- Coexisting conditions are common including:
 - Chronic fatigue, fibromyalgia, migraine headaches,
 - interstitial cystitis, lower back pain, and anxiety/depression
- Willing to accept >2% risk of death in return for a 98% chance of cure
 - >50% willing to give up caffeine or alcohol, 40% would give up sex for 1 month in exchange of 1 month of relief

Lacy BE et al. Am J Gastroenterol. 2021;116:17-44; Ballou S et al. Clin Gastroenterol Hepatol. 2019 Aug 13; Grover M et al. Plos One. 2021; 16(1); Anne F et al. Gastroenterology. 162 (2) 2022: 621-644.

Diagnostic Algorithm for IBS



Rome IV Diagnostic algorithms for common GI symptoms 2016.

Diagnostic Testing for Patients With Symptoms Suggestive of IBS


Test Recommended

- CBC, TSH
- IBS-D
 - CRP or fecal calprotectin
 - IgA TtG ± quantitative IgA
 - When colonoscopy performed, obtain random biopsies
 - Fecal bile acids or serum $7\alpha C4$ where available
 - Giardia Antigen
- IBS-C
 - Consider KUB r/o fecal loading (IBS-M)
 - Anorectal physiology testing if symptoms suggest pelvic floor dysfunction (IBS-C)

Test Not Recommended Routinely

- Stool testing including O&P (other than giardia)
 - With no travel to high-risk areas
- Colonoscopy < 45 years of age
- Food allergy or sensitivity testing
- Lactulose or glucose breath testing
- Imaging: X-ray, Ultrasound, CT, MRI

7αC4 = 7α-hydroxy-4-cholesten-3-one; CBC, complete blood count; CRC, colorectal screening; CRP, C-reactive protein; Ttg, tissue transglutaminase. Chey WD et al. *JAMA*. 2015;313(9):949-958; Smalley W et al. *Gastroenterology*. 2019; 157: 851–854; Lacy BE et al. *Am J Gastroenterology*. 2021;116:17–44; Moayyedi P et al. *J Can Assoc Gastroenterol*. 2019;2:6–29; Vasant DH et al. *Gut*. 2021; 70: 1214–1240.




*Selection of the medication should be based on the clinical features and needs of the patient.

Gastroenterology. 2022;163(1):118:136:cyclic antidepressant; SNRI, serotonin-norepinephrine reuptake inhibitor; PEG, polyethylene glycol; CBT, cognitive behavioral therapy

Low FODMAP Diet Systematic Review and Network Meta-Analysis

13 Studies Global IBS symptoms Low FODMAP diet was superior to other interventions




Antispasmodics

- Peppermint Oil
 - Enteric coated, delayed release
 - Meta-analyses1 support efficacy in IBS
 - NNT = 4 global improvement; NNT =7 abdominal pain
- Anticholinergics
 - Hyoscyamine, dicyloamine
 - Small, single-center, older studies with inconsistent results
 - Extensive experience in improving intermittent pain, frequently used prn

1. Ingrosso MR et al. Aliment Pharmacol Ther. 2022 Sep;56(6):932-941.

Bile Acids in IBS-D

- Bile acid malabsorption: • prevalence estimates 25-50% in IBS-D
- Open-label trial with BA . sequestrant in IBS showed promise in relieving symptoms
- FGF-19 regulates BA synthesis ۰
 - FGF19 is released from the ileal enterocytes in response to bile acids and suppresses bile acids synthesis in hepatocytes




Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid

Camilleri M. Gut Liver. 2015;9:332-339; Bajor A et al. Gut 2015;64:84-92; Camilleri M et al. Aliment Pharmacol Ther. 2015;41:438-48.

Gastroenterology 2023:∎:1-3

Rifaximin for IBS-D

Retreatment Efficacy FDA Responder




Original Research



Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points

Brian E. Lacy, MD, PhD¹; Lin Chang, MD²; Satish S.C. Rao, MD, PhD³; Zeev Heimanson, PharmD⁴; and Gregory S. Sayuk, MD, MPH⁵


A novel tri-symptom composite end point (abdominal pain, bloating, fecal urgency),



Lembo A et al. Gastroenterology. 2016;151(6):1113-1121; Lacy B et al. Clinical Therapeutics. 2023;45(3):198-209.

Eluxadoline a Mu-opioid Agonist for IBS-D

- μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist
- 3 RCT, 3235 patients
- Dosing: 100 mg BID
- AEs: Constipation, abdominal pain, SO spasm, pancreatitis
 - Contraindicated if no GB or h/o pancreatitis, heavy ETOH users




Composite responder defined as: ≥30% reduction in worst abdominal pain AND improvement in stool consistency of <5 on the BSFS for ≥ 50% of days in the trial.

Fujita W et al. *Biochemical Pharmacology*. 2014;92(3):448-4565; Wade PR et al. *British Journal of Pharmacology*. 2012;167(5):1111-1125; Lembo AJ et al. *N Engl J Med*. 2016;374(3):242-253.

Eluxadoline for IBS-D: Phase IV Trial Loperamide Failures


- Self-report failure to respond to loperamide failures in the prior 12 months to adequately control IBS-D symptoms
- AE rates comparable in both groups; no SAEs



Eluxadoline 100 mg BID (n=174)
Placebo BID (n=172)

Primary Composite = Patient met composite response criteria on \geq 50% of days, defined as \geq 40% improvement in WAP c/w BL and BSS <5 OR absence of a BM if accompanied by \geq 40% improvement in WAP. Secondary Stool Consistency defined as BSS <5 on \geq 50% of days. Secondary WAP defined as \geq 40% improvement in WAP compared to BL, on \geq 50% of days. Brenner DM et al. *Am J Gastroenterol.* 2019:114(9):1502-1511.

Efficacy of IBS-D Treatment: Network Meta-Analysis



"We found all drugs to be superior to placebo, but alosetron and ramosetron appeared to be the most effective."

Black CJ et al. Gut. 2019 Apr 17. pii: gutjnl-2018-318160.

ACG and AGA Guidelines: Recommendations for IBS-D Therapies

	ACG Recommendation ¹			AGA Recommendation ²			
	For or Against	Туре	Quality of evidence	For or Against	Туре	Quality of evidence	
Loperamide				+	Conditional	Very low	
Rifaximin Retreatment ^b	+	Strong	Moderate	+ +	Conditional Conditional	Moderate Moderate	
Alosetron ^a	+ ^a	Conditional	Low	+	Conditional	Moderate	
Eluxadoline	+	Conditional	Moderate	+	Conditional	Moderate	
Bile acid sequestrants	-	Conditional	Very low				

Treatment comparisons should not be made. For all recommendations, the treatment is recommended or suggested over no drug treatment.


+, Recommends or suggests use; -, Recommends or suggests against use.

^aLimited to women with severe symptoms who have failed conventional therapy.

^bIn patients with initial response to rifaximin who develop recurrent symptoms.


1. Lacy BE et al. Am J Gastroenterology. 2021;116:17-44; 2. Lembo A et al. Gastroenterology. 2022;163(1):137-151.

Clinical Decision Support Tool: IBS Treatment




Chang, Sultan, Lembo *Selection of the medication should be based on the clinical features and needs of the patient. TCA, tricyclic antidepressant; SNRI, serotonin-norepinephrine reuptake inhibitor; PEG, polyethylene glycol; CBT, cognitive Gastroenterology. 202_behavioral therapy

Secretagogues for IBS-C Mechanism of Action




Lubiprostone (CLC2 Activator) for IBS-C

IBS-C dose: 8 mcg BID only approved in women




Drossman DA et al. Aliment Pharmacol Ther. 2009;29:329-341; Chang L et al. Gastroenterology. 2022;163:118-136.

Linaclotide (GC-C Agonist) for IBS-C




Chang L et al. Gastroenterology. 2022;163:118-136; Chang L et al. Am J Gastro. 2021.


Plecanatide (GC-C Agonist) for IBS-C




Brenner D et al. Am J Gastroenterol. 2018; Chang L et al. Gastroenterology. 2022;163:118-136.

Tenapanor for IBS-C








Abdominal Symptom (AS3) Composite score: abdominal pain, discomfort, bloating

Efficacy of IBS-C Treatments Network Meta-Analysis



"Efficacy similar among individual drugs and dosages for most end points"


ACG and AGA Guidelines: Recommendations for IBS-C Therapies

	ACG Recommendation ¹			AGA Recommendation ²			
	For or Against	Туре	Quality of evidence	For or Against	Туре	Quality of evidence	
PEG	-	Conditional	Low	+	Conditional	Low	
Lubiprostone	+	Strong	Moderate	+	Conditional	Moderate	
GC-C agonists	+	Strong	High				
Linaclotide Plecanatide				+ +	Strong Conditional	High Moderate	
Tegaserod ^a	+	Conditional	Low	+	Conditional	Moderate	
Tenapanor				+	Conditional	Moderate	

Treatment comparisons should not be made. For all recommendations, the treatment is recommended or suggested over no drug treatment.

+, Recommends or suggests use; -, Recommends or suggests against use.

aLimited for use of tegaserod in women <65 years of age with ≤1 cardiovascular risk factors who have not adequately responded to secretagogues. 1. Lacy BE et al. *Am J Gastroenterology*. 2021;116:17–44; 2. Chang L et al. *Gastroenterology*. 2022;163(1):118-136.



*Selection of the medication should be based on the clinical features and needs of the patient.

TCA, tricyclic antidepressant; SNRI, serotonin-norepinephrine reuptake inhibitor; PEG, polyethylene glycol; CBT, cognitive behavioral therapy

Chang, Sultan, Lembo, et al. Gastroenterology. 2022;163(1):118-136.

Neuromodulation for DGBI

SSRIs (paroxetine, fluoxetine, sertraline,

citalopram, escitalopram)

When anxiety, depression, and phobic features are prominent with FGIDs

TCAs (amitriptyline, nortriptyline, imipramine, desipramine)

First-line treatment when pain is dominant in FGIDs

Tetracyclic antidepressant

(mirtazapine, mianserin, trazodone)

Treatment of early satiety nausea/vomiting, weight loss and disturbed sleep

SNRIs (duloxetine, venlafaxine, desvenlafaxine, milnacipran)

Treatment when pain is dominant in FGIDs or when side effects from TCAs preclude treatment

Insufficient effect or dosage restricted by side effects

Augmentation

Azapirones (buspirone, tandospirone) Dyspeptic features, anxiety prominent

Delta ligands (gabapentin, pregabalin) Abdominal wall pain, comorbid fibromyalgia

SSRI When anxiety and phobic features dominant Atypical antipsychotics Pain with disturbed sleep (quetiapine) anxiety, nausea (olanzapine, sulpiride) additional somatic symptoms ("side effects")


Bupropion Fatigue and sleepiness prominent Psychological Treatment CBT when maladaptive cognitions and catastrophizing present

DBT, EMDR with history of PTSD or trauma

Hypnosis, Mindfulness, Relaxation as alternative treatments

Cognitive Behavioral Therapy (CBT)

- Prospective randomized active comparator study; Rome III > moderate severity
- N=436 SUNY Buffalo/ Northwestern University
- MC-CBT ((N=146) 4 sessions); S-CBT ((N-146) 10 sessions); EDU ((N=145) 4 sessions)
- 1^o Endpoint: CGI-I (1-7 scale w/6-7 moderate/substantial improvement considered a responder



MCCBT-Minimal Contact CBT; S-CBT-Standard CBT; EDU-Education; CGI-I (Clinical Global Impressions-Improvement-Scale; GE (Gastroenterologist). Lackner J, Jaccard J, Keefer LK, Brenner DM, et al. *Gastroenterology*. 2018. (epub ahead of print).



Articles & Issues 🗸 For Authors 🗸 Journal Info 🖍 ACG Clinical Guidelines 🛛 Collections 🗸

THE RED SECTION: DIGITAL DIALOGUE

Behavioral Health Digital Therapeutics for Patients With Irritable Bowel Syndrome: A Primer for Gastroenterologists

Saleh, Zachary M. MD¹; Chey, William D. FACG, AGAF, FACP, RFF²; Berry, Sameer K. MD, MBA²

Author Information 😔

The American Journal of Gastroenterology ():10.14309/ajg.000000000002220, March 20, 2023. | DOI: 10.14309/ajg.0000000002220

BUY PAP

Metrics

Gut-Directed Hypotherapy

Regulora (MetaMe Health) - FDA-cleared, UNC protocols

Nerva - Available to download. <u>Dr. Simone Peters</u> and Monash Univ. includes psychoeducation readings, and breathing techniques

Non-IBS options: <u>Hypnosis</u>, <u>OpenCare 2.0</u>, and <u>Sympto Health</u>

Cognitive Behavioral Therapy

Mahana IBS - FDA-cleared

Zemedy (Bold Health) - Available to download. Chat bot AI Coach named Elle

ACG and AGA Guidelines: General IBS Therapies

	ACG Recommendation ¹			AGA Recommendation ²		
	For or Against	Туре	Quality of evidence	For or Against	Туре	Quality of evidence
Low FODMAP diet	+	Conditional	Very low			
Antispasmodics	_	Conditional	Low	+	Conditional	Low
Peppermint oil	+	Conditional	Low			
Probiotics	_	Conditional	Very low			
TCAs	+	Strong	Moderate	+	Conditional	Low
SSRIs				-	Conditional	Low
Gut-directed psychotherapies	+	Conditional	Very low			

+, Recommends or suggests use; –, Recommends or suggests against use.

1. Lacy BE et al. Am J Gastroenterology. 2021;116:17–44; 2. Lembo A et al. Gastroenterology. 2022;163(1):137-151.

Probiotics in IBS

ACG IBS Guideline

Recommendation


We suggest against probiotics for the treatment of global IBS symptoms.

Conditional recommendation; very low level of evidence.


Although a number of individual studies have shown efficacy, in general, most studies are of low quality (single center, lack of rigorous endpoints)

Lack of consistency (i.e., Single vs. multiorganism cocktails, dose of probiotic, combination treatments)

The Short-term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism rather than Diversity Regulation




Fecal Microbiota Transplant for IBS




Weights are from random effects analysis Heterogeneity: $l^2 = 79\%$, $\chi_3^2 = 14.47$ (p < 0.01) Clinical Response to FMT: z = -0.22 (p = 0.83)

Figure 2 Forest plot of all studies for efficacy of FMT vs placebo on global improvement of IBS symptoms. CI, confidence interval; FMT, fecal microbiota transplantation; IBS, irritable bowel syndrome; RR, risk ratio.



- Single 'super donor'
- Frozen FMT
- Distal duodenum via EGD
- 165 IBS patients (all subtype)
- Responder: decrease > 50 IBS-SSS



62 (2:1) IBS-D/M with severe bloating 2 healthy donors Fresh FMT via NJT

Adequate relief of IBS and bloating at week 12 Highe diversity and bacterial composition at baseline – greater success

Xu et al. Am J Gastroenterol. 2019;00:1–8; El-Sahly M et al. Gut. 2020 May;69(5):859-867; Holvoet T et al. Gastroenterology. 2021;160(1):145-157.

Take Home Points

- Make a positive diagnosis (exclude alarm features)
- Diet, lifestyle modifications, OTC (loperamide, PEG, fiber) therapies are first line
- Best clinical trial evidence
 - **IBS-D:** Rifaximin, Eluxadoline, Alosetron
 - **IBS-C:** Linaclotide, Plecanatide, Lubiprostone, Tegaserod
 - Pain: Peppermint oil (for all subtypes); TCAs, SNRIs (for IBS-D/M with pain)-allow 4 weeks minimum; antispasmodics
 - Psychological: CBT, hypnosis